Prognostic factors for cytology-positive gastric cancer: a multicenter retrospective analysis

Background The prognosis of patients with gastric cancer and positive peritoneal lavage cytology is poor, even after gastrectomy. Though the standard therapy for this population is radical gastrectomy followed by S-1 chemotherapy, treatments vary among institutions and eras. We conducted a multicent...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical oncology 2021-05, Vol.26 (5), p.858-866
Main Authors: Endo, Shunji, Nishikawa, Kazuhiro, Ikenaga, Masakazu, Fujitani, Kazumasa, Kawada, Junji, Yamatsuji, Tomoki, Kubota, Hisako, Higashida, Masaharu, Fujiwara, Yoshinori, Ueno, Tomio
Format: Article
Language:English
Subjects:
Cancer Research
Cancer therapies
Cellular biology
Chemotherapy
Confidence intervals
Cytology
Gastrectomy
Gastric cancer
Gastrointestinal surgery
Lymph nodes
Lymphatic system
Medical prognosis
Medical records
Medicine
Medicine & Public Health
Metastases
Metastasis
Multivariate analysis
Oncology
Original Article
Peritoneum
Risk factors
Surgical Oncology
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The prognosis of patients with gastric cancer and positive peritoneal lavage cytology is poor, even after gastrectomy. Though the standard therapy for this population is radical gastrectomy followed by S-1 chemotherapy, treatments vary among institutions and eras. We conducted a multicenter retrospective study to investigate the prognostic factors for cytology-positive gastric cancer. Methods We reviewed the medical records obtained from 6 institutions, covering 2000–2019. There were 128 patients with positive cytology and no other distant metastases that underwent R1 gastrectomy. Univariate and multivariate analyses to identify prognostic factors for overall survival were conducted using Cox’s proportional hazards models. Results The median overall survival time was 18.6 months. In univariate analyses, age (≥ 80 years vs. 
ISSN:1341-9625
1437-7772
DOI:10.1007/s10147-021-01873-4